Solubility Advantage of Pharmaceutical Cocrystals
Source abstract
Abstract
Pharmaceutical cocrystals can improve solubility, dissolution, and bioavailability of poorly water soluble drugs. However, true cocrystal solubility is not readily measured for highly soluble cocrystals because they can transform to the most stable drug form in solution. The objectives of this study are to develop a method to estimate the cocrystal solubility in pure solvent and establish the influence of constituent drug and ligand (i.e., coformer) properties. Cocrystal solubility and solubility product were derived from transition concentration measurements where a solution is in equilibrium with solid drug and cocrystal. Transition concentrations and solubilities are reported for carbamazepine cocrystals in water, ethanol, isopropanol, and ethyl acetate. The aqueous solubility for seven carbamazepine cocrystals was estimated to be 2−152 times greater than the solubility of the stable carbamazepine dihydrate form. Cocrystal solubility is shown to be directly proportional to the solubility of constituent reactants for carbamazepine, caffeine, and theophylline cocrystals. The ligand transition concentration is also correlated with ligand solubility. Transition concentration measurements reveal drug solubilization by ligand for several of the cocrystals studied. The correlation established between constituent and cocrystal solubility was not effectively predicted by fusion properties of the various crystal forms considered.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Crystallography and molecular interactions · Crystallization and Solubility Studies · Phenothiazines and Benzothiazines Synthesis and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109
References (60)
Show source-provided references
1. Lipinski, C. A.,Solubility in water and DMSO: issues and potential solutions. InPharmaceutical Profiling in Drug Discovery for Lead Selection;Borchardt, R. T., Kerns, E. H., Lipinski, C. A., Thakker, D. R., Wang, B., Eds.AAPS Press:Arlington, VA, 2004; pp 93−125.
2. Takagi T. · Mol. Pharm. · 2006 · 3 · 63110.1021/mp0600182 ↗
3. Amidon G. L. · Pharm. Res. · 1995 · 12 · 41310.1023/A:1016212804288 ↗
4. Bak A. · J. Pharm. Sci. · 2008 · 97 · 394210.1002/jps.21280 ↗
5. Hickey M. B. · Eur. J. Pharm. Biopharm. · 2007 · 67 · 11210.1016/j.ejpb.2006.12.016 ↗
6. McNamara D. P. · Pharm. Res. · 2006 · 23 · 188810.1007/s11095-006-9032-3 ↗
7. Remenar J. F. · J. Am. Chem. Soc. · 2003 · 125 · 845610.1021/ja035776p ↗
8. Remenar J. F. · Mol. Pharm. · 2007 · 4 · 38610.1021/mp0700108 ↗
9. Childs S. L. · Cryst. Growth Des. · 2007 · 7 · 129110.1021/cg060742p ↗
10. Higuchi W. I. · J. Pharm. Sci. · 1965 · 54 · 810.1002/jps.2600540103 ↗
11. Serajuddin A. T. · J. Pharm. Sci. · 1985 · 74 · 14810.1002/jps.2600740209 ↗
12. Serajuddin A. T. · J. Pharm. Sci. · 1985 · 74 · 14210.1002/jps.2600740208 ↗
13. Stahl, P. H.; Wermuth, C. G.International Union of Pure and Applied Chemistry Handbook of Pharmaceutical Salts: Properties, Selection, And Use;Wiley-VCH:Weinheim, Germany, 2002; pxiv.
14. Nehm S. J. · Cryst. Growth Des. · 2006 · 6 · 59210.1021/cg0503346 ↗
15. Bhattachar S. N. · Drug Discovery Today · 2006 · 11 · 101210.1016/j.drudis.2006.09.002 ↗
16. Corrigan O. I. · 2002 · v
17. Miyazaki S. · Chem. Pharm. Bull. (Tokyo) · 1975 · 23 · 119710.1248/cpb.23.1197 ↗
18. Miyazaki S. · J. Pharm. Sci. · 1981 · 70 · 59410.1002/jps.2600700604 ↗
19. Jayasankar A. · Cryst. Growth Des. · 2009 · 9 · 88910.1021/cg800632r ↗
20. Nicoli S. · J. Pharm. Sci. · 2008 · 97 · 483010.1002/jps.21341 ↗
21. Rodríguez-Hornedo N. · Mol. Pharm. · 2006 · 3 · 36210.1021/mp050099m ↗
22. Klussmann M. · Angew. Chem., Int. Ed. · 2006 · 45 · 798510.1002/anie.200602520 ↗
23. Childs S. L. · Cryst. Eng. Comm. · 2008 · 10 · 85610.1039/b715396a ↗
24. Chiarella R. A. · Cryst. Growth Des. · 2007 · 7 · 122310.1021/cg070218y ↗
25. Kobayashi Y. · Int. J. Pharm. · 2000 · 193 · 13710.1016/S0378-5173(99)00315-4 ↗
26. Lang M. · J. Pharm. Sci. · 2002 · 91 · 118610.1002/jps.10093 ↗
27. Rodriguez-Spong B. · Adv. Drug Delivery Rev. · 2004 · 56 · 24110.1016/j.addr.2003.10.005 ↗
28. Childs S. L. · Cryst. Growth Des. · 2008
29. Bethune, S.; Huang, N.; Jayasankar, A.; Rodríguez-Hornedo, N.Understanding and Predicting the Effect of Cocrystal Components and pH on Cocrystal Solubility.Cryst. Growth Des.2009,submitted.10.1021/cg9001187 ↗
30. Bethune, S. J.Thermodynamic and kinetic parameters that explain solubility and crystallization of pharmaceutical cocrystals.Ph.D. Thesis,University of Michigan,Ann Arbor, MI, 2008.
31. Nehm S. J. · AAPS J. · 2006
32. Rodríguez-Hornedo, N.; Nehm, S. J.; Jayasankar, A.Cocrystals: Design, Properties and Formation Mechanisms. InEncyclopedia of Pharmaceutical Technology,3rded.Informa HealthCare:London, 2006; pp615−635.
33. Cooke C. L. · Cryst. Growth Des. · 2008 · 8 · 348310.1021/cg800621q ↗
34. Jacques J. · 1991
35. Klussmann M. · Angew. Chem., Int. Ed. · 2006 · 45 · 798510.1002/anie.200602520 ↗
36. Glasstone S. · 1948
37. Reddy L. S. · Cryst. Growth Des. · 2009 · 37810.1021/cg800587y ↗
38. Grant, D. J. W.; Higuchi, T.,Solubility Behavior of Organic Compounds;Wiley:New York, 1990; pliii.
39. Yalkowsky, S. H.Solubility and Solubilization in Aqueous Media;American Chemical Society:Washington, D.C., 1999; 61−77.
40. Porter III W. W. · Cryst. Growth Des. · 2008 · 8 · 1410.1021/cg701022e ↗
41. Shan N. · Drug Discovery Today · 2008 · 13 · 44010.1016/j.drudis.2008.03.004 ↗
42. Das S. N. · Proc. Chem. Soc. London · 1961 · 373
43. Speakman J. C. · J. Chem. Soc. · 1940 · 85510.1039/jr9400000855 ↗
44. Darken L. S. · J. Am. Chem. Soc. · 1941 · 63 · 100710.1021/ja01849a033 ↗
45. Pinching G. D. · J. Res. Natl. Inst. Stand. Technol. · 1950 · 45 · 44410.6028/jres.045.049 ↗
46. Newton D. W. · Drug Intell. Clin. Pharm. · 1978 · 12 · 546
47. Bray L. G. · J. Chem. Soc. · 1957 · 240510.1039/jr9570002405 ↗
48. Pudipeddi M. · J. Pharm. Sci. · 2005 · 94 · 92910.1002/jps.20302 ↗
49. Hancock B. C. · Pharm. Res. · 2000 · 17 · 39710.1023/A:1007516718048 ↗
50. Jones P. H. · J. Pharm. Sci. · 1969 · 58 · 33710.1002/jps.2600580311 ↗
51. Magerlein B. J. · J. Pharm. Sci. · 1965 · 54 · 106510.1002/jps.2600540729 ↗
52. Agharkar S. · J. Pharm. Sci. · 1976 · 65 · 74710.1002/jps.2600650533 ↗
53. Wells, J. I.,Pharmaceutical Preformulation: The Physicochemical Properties of Drug Substances;Horwood, E., Ed.Halsted Press:Chichester, U.K., 1988; p227.
54. Anderson B. D. · J. Pharm. Sci. · 1985 · 74 · 81510.1002/jps.2600740803 ↗
55. Sanghvi R. · Int. J. Pharm. · 2007 · 336 · 3510.1016/j.ijpharm.2006.11.025 ↗
56. Black S. N. · J. Pharm. Sci. · 2007 · 96 · 105310.1002/jps.20927 ↗
57. Aakeroy C. B. · Chem. Commun. · 2006 · 144510.1039/b517118k ↗
58. Stanton M. K. · Cryst. Growth Des. · 2008 · 8 · 385610.1021/cg800173d ↗
59. Rubino J. T. · J. Pharm. Sci. · 1989 · 78 · 48510.1002/jps.2600780614 ↗
60. Thomas E. · Int. J. Pharm. · 1996 · 130 · 17910.1016/0378-5173(95)04269-5 ↗